

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/101957 A1

(51) International Patent Classification⁷: **C07D 205/04,**
A61K 31/396

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE03/00859

(22) International Filing Date: 27 May 2003 (27.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0201661-6 31 May 2002 (31.05.2002) SE

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations *AF*,
AG, *AL*, *AM*, *AT*, *AU*, *AZ*, *BA*, *BB*, *BG*, *BR*, *BY*, *BZ*, *CA*, *CH*,
CN, *CO*, *CR*, *CU*, *CZ*, *DE*, *DK*, *DM*, *DZ*, *EC*, *EE*, *ES*, *FI*,
GB, *GD*, *GE*, *GH*, *GM*, *HR*, *HU*, *ID*, *IL*, *IN*, *IS*, *JP*, *KE*, *KG*,
KP, *KR*, *KZ*, *LC*, *LK*, *LR*, *LS*, *LT*, *LU*, *LV*, *MA*, *MD*, *MG*, *MK*,
MN, *MW*, *MX*, *MZ*, *NI*, *NO*, *NZ*, *OM*, *PH*, *PL*, *PT*, *RO*, *RU*,
SC, *SD*, *SE*, *SG*, *SK*, *SL*, *TJ*, *TM*, *TN*, *TR*, *TT*, *TZ*, *UA*, *UG*,
UZ, *VC*, *VN*, *YU*, *ZA*, *ZM*, *ZW*, ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

(71) Applicant (*for all designated States except US*): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): AHLQVIST, Matti
[SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Möl-
ndal (SE). BOHLIN, Martin [SE/SE]; AstraZeneca R & D
Södertälje, S-151 85 Södertälje (SE). INGHARDT, Tord
[SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Möl-
ndal (SE). LUNDBLAD, Anita [SE/SE]; AstraZeneca R
& D Mölndal, S-431 83 Mölndal (SE). SIGFRIDSSON,
Carl-Gustaf [SE/SE]; AstraZeneca R & D Mölndal, s-431
83 Mölndal (SE).

(74) Agent: ASTRAZENCA AB; Global Intellectual Property,
S-151 85 Södertälje (SE).

Published:


— with international search report

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NEW SALTS

WO 03/101957 A1



(e.g. thrombosis) or as anticoagulants.

(57) Abstract: There is provided
pharmaceutically-acceptable acid
addition salts of compounds of
formula (I), wherein R¹ represents
C₁₋₂ alkyl substituted by one or more
fluoro substituents; R² represents
C₁₋₂ alkyl; and n represents 0, 1
or 2, which salts are useful as
prodrugs of competitive inhibitors
of trypsin-like proteases, such as
thrombin, and thus, in particular,
in the treatment of conditions where
inhibition of thrombin is required